PhenoVista Biosciences provides high content imaging-based phenotypic assay development and screening services.
PhenoVista Biosciences has raised $3.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2022.
PhenoVista Biosciences's investors include BroadOak Capital Partners, U.S. Department of Health & Human Services, Life Sciences Corporate Venture Capital.
PhenoVista Biosciences is headquartered in San Diego, United States.
PhenoVista Biosciences provides high content imaging-based phenotypic assay development and screening services.
PhenoVista Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PhenoVista Biosciences — Funding & Investors." VCBacked, December 13, 2022, https://www.vcbacked.co/company/phenovista-biosciences. Accessed August 17, 2026.
VCBacked. (2022). PhenoVista Biosciences — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/phenovista-biosciences
{{cite web |title=PhenoVista Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/phenovista-biosciences |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated